Concepedia

Kimberly K. Adkison

KK

Statistics

Publications

25

Citations

2.2K

H-Index

21

Active since

1997

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

GlaxoSmithKline (United Kingdom)

Janssen (Belgium)

Bristol-Myers Squibb (United States)

Kimberly K. Adkison is an author at GlaxoSmithKline (United States) specializing in pharmacology, pharmacy, and pharmacokinetics.

ORCID

Publications per year

1997–2019

25

Publications

25

Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

Kelly M. Mahar Doan, Joan E. Humphreys, Lindsey O. Webster et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 626 citations

, , +17

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison et al. · Journal of Pharmaceutical Sciences · 2011 · 201 citations

, , +15

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones et al. · Journal of Pharmaceutical Sciences · 2011 · 171 citations

, , +14

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

W. Garrett Nichols, H. M. Steel, Tab Bonny et al. · Antimicrobial Agents and Chemotherapy · 2007 · 146 citations

, , +17

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland et al. · Journal of Pharmaceutical Sciences · 2011 · 135 citations

, , +17

1–5 of 25